Inducible	O
nuclear	B-protein
factor	I-protein
binding	O
to	O
the	O
kappa	B-DNA
B	I-DNA
elements	I-DNA
of	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
enhancer	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
can	O
be	O
blocked	O
by	O
cyclosporin	O
A	O
in	O
a	O
signal-dependent	O
manner	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
is	O
thought	O
to	O
exert	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O
expression	O
of	O
a	O
distinct	O
set	O
of	O
lymphokine	B-DNA
genes	I-DNA
which	O
are	O
induced	O
upon	O
T-cell	O
activation	O
,	O
among	O
them	O
the	O
gene	O
coding	O
for	O
interleukin-2	B-protein
.	O

In	O
addition	O
,	O
the	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
partially	O
suppressed	O
.	O

To	O
better	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
suppression	O
by	O
CsA	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
this	O
drug	O
on	O
transcription	B-protein
factors	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

Here	O
we	O
report	O
that	O
the	O
formation	O
of	O
two	O
distinct	O
mitogen-inducible	B-protein
DNA-binding	I-protein
complexes	I-protein
,	O
the	O
kappa	B-protein
B	I-protein
complex	I-protein
within	O
the	O
HIV	B-DNA
enhancer	I-DNA
and	O
the	O
NFAT-1	B-protein
complex	I-protein
within	O
the	O
interleukin-2	B-DNA
enhancer	I-DNA
,	O
is	O
inhibited	O
in	O
the	O
presence	O
of	O
CsA	O
.	O

The	O
kappa	O
B-binding	O
activity	O
with	O
the	O
HIV	B-DNA
enhancer	I-DNA
is	O
inhibited	O
only	O
if	O
it	O
is	O
activated	O
via	O
the	O
mitogen	B-protein
phytohemagglutinin	B-protein
whereas	O
phorbol	O
myristate	O
acetate-mediated	O
activation	O
is	O
completely	O
insensitive	O
to	O
the	O
drug	O
.	O

This	O
suggests	O
a	O
model	O
in	O
which	O
functionally	O
indistinguishable	O
kappa	B-protein
B	I-protein
complexes	I-protein
can	O
be	O
activated	O
via	O
two	O
separate	O
pathways	O
of	O
signal	O
transduction	O
distinguishable	O
by	O
CsA	O
.	O

JoURNAL	NULL
OF	NULL
VIROLOGY	NULL
,	NULL
Aug.	NULL
1990	NULL
,	NULL
p.	NULL
4037-4041	NULL
0022-538	NULL
X/90/084037-05	NULL
$	NULL
02.00/0	NULL
Copyright	NULL
©	NULL
1990	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

64	NULL
,	NULL
No	NULL
.	NULL

8	NULL
Inducible	NULL
Nuclear	NULL
Factor	NULL
Binding	NULL
to	NULL
the	NULL
kB	NULL
Elements	NULL
of	NULL
the	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Enhancer	NULL
in	NULL
T	NULL
Cells	NULL
Can	NULL
Be	NULL
Blocked	NULL
by	NULL
Cyclosporin	NULL
A	NULL
in	NULL
a	NULL
Signal-Dependent	NULL
Manner	NULL
ALBRECHT	NULL
SCHMIDT	NULL
,	NULL
'	NULL
LOTHAR	NULL
HENNIGHAUSEN	NULL
,	NULL
``	NULL
anp	NULL
ULRICH	NULL
SIEBENLIST'*	NULL
Laboratory	NULL
of	NULL
Immunoregulation	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Allergy	NULL
and	NULL
Infectious	NULL
Diseases	NULL
,	NULL
``	NULL
and	NULL
Laboratory	NULL
of	NULL
Biochemistry	NULL
and	NULL
Metabolism	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Diabetes	NULL
and	NULL
Digestive	NULL
and	NULL
Kidney	NULL
Diseases	NULL
,	NULL
``	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20892	NULL
Received	NULL
26	NULL
February	NULL
1990/Accepted	NULL
4	NULL
May	NULL
1990	NULL
Cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
is	NULL
thought	NULL
to	NULL
exert	NULL
its	NULL
immunosuppressive	NULL
effects	NULL
by	NULL
inhibiting	NULL
the	NULL
expression	NULL
of	NULL
a	NULL
distinct	NULL
set	NULL
of	NULL
lymphokine	NULL
genes	NULL
which	NULL
are	NULL
induced	NULL
upon	NULL
T-cell	NULL
activation	NULL
,	NULL
among	NULL
them	NULL
the	NULL
gene	NULL
coding	NULL
for	NULL
interleukin-2	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
is	NULL
partially	NULL
suppressed	NULL
.	NULL

To	NULL
better	NULL
understand	NULL
the	NULL
molecular	NULL
mechanisms	NULL
underlying	NULL
suppression	NULL
by	NULL
CsA	NULL
,	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
effects	NULL
of	NULL
this	NULL
drug	NULL
on	NULL
transcription	NULL
factors	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Here	NULL
we	NULL
report	NULL
that	NULL
the	NULL
formation	NULL
of	NULL
two	NULL
distinct	NULL
mitogen-inducible	NULL
DNA-binding	NULL
complexes	NULL
,	NULL
the	NULL
«	NULL
B	NULL
complex	NULL
within	NULL
the	NULL
HIV	NULL
enhancer	NULL
and	NULL
the	NULL
NFAT-1	NULL
complex	NULL
within	NULL
the	NULL
interleukin-2	NULL
enhancer	NULL
,	NULL
is	NULL
inhibited	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
.	NULL

The	NULL
«	NULL
B-binding	NULL
activity	NULL
with	NULL
the	NULL
HIV	NULL
enhancer	NULL
is	NULL
inhibited	NULL
only	NULL
if	NULL
it	NULL
is	NULL
activated	NULL
via	NULL
the	NULL
mitogen	NULL
phytohemagglutinin	NULL
,	NULL
whereas	NULL
phorbol	NULL
myristate	NULL
acetate-mediated	NULL
activation	NULL
is	NULL
completely	NULL
insensitive	NULL
to	NULL
the	NULL
drug	NULL
.	NULL

This	NULL
suggests	NULL
a	NULL
model	NULL
in	NULL
which	NULL
functionally	NULL
indistinguishable	NULL
«	NULL
B	NULL
complexes	NULL
can	NULL
be	NULL
activated	NULL
via	NULL
two	NULL
separate	NULL
pathways	NULL
of	NULL
signal	NULL
transduction	NULL
distinguish	NULL
able	NULL
by	NULL
CsA	NULL
.	NULL

Cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
is	NULL
a	NULL
clinically	NULL
important	NULL
immunosuppressive	NULL
drug	NULL
which	NULL
suppresses	NULL
induction	NULL
of	NULL
a	NULL
number	NULL
of	NULL
genes	NULL
,	NULL
including	NULL
that	NULL
coding	NULL
for	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
9	NULL
,	NULL
25	NULL
)	NULL
,	NULL
and	NULL
to	NULL
some	NULL
extent	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
(	NULL
HIV	NULL
)	NULL
(	NULL
26	NULL
,	NULL
28	NULL
)	NULL
.	NULL

The	NULL
molecular	NULL
mechanisms	NULL
of	NULL
this	NULL
suppression	NULL
are	NULL
unknown	NULL
,	NULL
but	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
CsA	NULL
inhibits	NULL
the	NULL
induced	NULL
expression	NULL
of	NULL
several	NULL
genes	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
(	NULL
10	NULL
,	NULL
14	NULL
)	NULL
.	NULL

Two	NULL
tandemly	NULL
repeated	NULL
kB	NULL
sequence	NULL
elements	NULL
are	NULL
essential	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
HIV	NULL
genome	NULL
,	NULL
and	NULL
these	NULL
elements	NULL
confer	NULL
enhancer	NULL
function	NULL
(	NULL
19	NULL
)	NULL
.	NULL

This	NULL
enhancer	NULL
element	NULL
binds	NULL
inducible	NULL
nuclear	NULL
factors	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
factor	NULL
,	NULL
and	NULL
additional	NULL
,	NULL
possibly	NULL
related	NULL
factors	NULL
including	NULL
HIVEN-86	NULL
(	NULL
2	NULL
,	NULL
3	NULL
,	NULL
8	NULL
,	NULL
19	NULL
)	NULL
.	NULL

«	NULL
kB	NULL
nuclear	NULL
factor-binding	NULL
elements	NULL
also	NULL
play	NULL
important	NULL
roles	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
gene	NULL
coding	NULL
for	NULL
IL-2	NULL
and	NULL
other	NULL
genes	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
11	NULL
,	NULL
15	NULL
,	NULL
16	NULL
,	NULL
22	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
kB	NULL
,	NULL
other	NULL
IL-2	NULL
enhancer	NULL
elements	NULL
appear	NULL
to	NULL
mediate	NULL
signal	NULL
transduction	NULL
,	NULL
and	NULL
some	NULL
of	NULL
these	NULL
elements	NULL
show	NULL
inducible	NULL
factor	NULL
binding	NULL
after	NULL
activation	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
4	NULL
,	NULL
6	NULL
,	NULL
11	NULL
,	NULL
16	NULL
,	NULL
22	NULL
,	NULL
24	NULL
)	NULL
.	NULL

Among	NULL
the	NULL
elements	NULL
that	NULL
show	NULL
inducible	NULL
factor	NULL
binding	NULL
is	NULL
the	NULL
site	NULL
termed	NULL
IL-2-IIA	NULL
by	NULL
us	NULL
(	NULL
4	NULL
)	NULL
and	NULL
NFAT-1-binding	NULL
site	NULL
by	NULL
others	NULL
(	NULL
24	NULL
)	NULL
,	NULL
which	NULL
has	NULL
been	NULL
implicated	NULL
directly	NULL
in	NULL
playing	NULL
a	NULL
major	NULL
role	NULL
during	NULL
transcriptional	NULL
activation	NULL
of	NULL
IL-2	NULL
(	NULL
6	NULL
,	NULL
24	NULL
)	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
kB	NULL
and	NULL
NFAT-1	NULL
complexes	NULL
in	NULL
T	NULL
cells	NULL
is	NULL
sensitive	NULL
to	NULL
CsA	NULL
,	NULL
whereas	NULL
activation	NULL
of	NULL
an	NULL
inducible	NULL
AP-1	NULL
complex	NULL
is	NULL
not	NULL
.	NULL

This	NULL
suggests	NULL
selective	NULL
action	NULL
of	NULL
the	NULL
drug	NULL
.	NULL

We	NULL
further	NULL
show	NULL
that	NULL
the	NULL
HIV-	NULL
«	NULL
kB-binding	NULL
complex	NULL
as	NULL
well	NULL
as	NULL
the	NULL
function	NULL
of	NULL
the	NULL
HIV	NULL
enhancer	NULL
in	NULL
transfection	NULL
experiments	NULL
is	NULL
completely	NULL
inhibited	NULL
when	NULL
mediated	NULL
through	NULL
a	NULL
phytohemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
-induced	NULL
signal	NULL
but	NULL
is	NULL
insensitive	NULL
to	NULL
a	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
-induced	NULL
signal	NULL
.	NULL

We	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
CsA	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
kB-binding	NULL
complex	NULL
of	NULL
the	NULL
HIV	NULL
long	NULL
terminal	NULL
repeat	NULL
in	NULL
T	NULL
cells	NULL
with	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

A	NULL
radio	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

4037	NULL
actively	NULL
labeled	NULL
oligonucleotide	NULL
fragment	NULL
representing	NULL
the	NULL
site	NULL
(	NULL
nucleotides	NULL
-104	NULL
to	NULL
-79	NULL
,	NULL
5-GGGACTTITT	NULL
CCGCTGGGGACTTTCCAG-3	NULL
'	NULL
[	NULL
19	NULL
]	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
(	NULL
10	NULL
pg	NULL
of	NULL
protein	NULL
)	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
20	NULL
pl	NULL
{	NULL
40	NULL
mM	NULL
NaCl	NULL
,	NULL
40	NULL
mM	NULL
KCI	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
20	NULL
mM	NULL
N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic	NULL
acid	NULL
[	NULL
HEPES	NULL
;	NULL
pH	NULL
7.9	NULL
]	NULL
,	NULL
approximately	NULL
7	NULL
%	NULL
glycerol	NULL
[	NULL
vol/vol	NULL
]	NULL
,	NULL
0.5	NULL
mM	NULL
dithio-threitol	NULL
,	NULL
25	NULL
wM	NULL
NPGB	NULL
,	NULL
1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
,	NULL
2	NULL
ug	NULL
of	NULL
poly	NULL
[	NULL
dI-dC	NULL
)	NULL
]	NULL
[	NULL
Pharmacia	NULL
)	NULL
}	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Resulting	NULL
complexes	NULL
were	NULL
separated	NULL
on	NULL
a	NULL
4	NULL
%	NULL
low-ionic-strength	NULL
polyacrylamide	NULL
gel	NULL
(	NULL
27	NULL
)	NULL
in	NULL
a	NULL
cold	NULL
room	NULL
.	NULL

Activation	NULL
of	NULL
T	NULL
cells	NULL
by	NULL
PHA-PMA	NULL
induced	NULL
the	NULL
binding	NULL
of	NULL
a	NULL
major	NULL
complex	NULL
(	NULL
termed	NULL
B	NULL
)	NULL
to	NULL
the	NULL
kB	NULL
enhancer	NULL
elements	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

An	NULL
additional	NULL
inducible	NULL
complex	NULL
(	NULL
termed	NULL
A	NULL
)	NULL
,	NULL
closely	NULL
spaced	NULL
and	NULL
slightly	NULL
more	NULL
slowly	NULL
migrating	NULL
,	NULL
could	NULL
also	NULL
be	NULL
discriminated	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Although	NULL
detected	NULL
repeat-edly	NULL
,	NULL
the	NULL
A	NULL
shift	NULL
was	NULL
weak	NULL
and	NULL
variable	NULL
in	NULL
strength	NULL
;	NULL
it	NULL
was	NULL
most	NULL
clearly	NULL
seen	NULL
when	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PHA	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
but	NULL
never	NULL
seen	NULL
when	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lane	NULL
7	NULL
)	NULL
.	NULL

The	NULL
nature	NULL
of	NULL
the	NULL
two	NULL
constitutively	NULL
present	NULL
complexes	NULL
is	NULL
unknown	NULL
;	NULL
they	NULL
were	NULL
essentially	NULL
unaffected	NULL
by	NULL
the	NULL
activation	NULL
protocols	NULL
.	NULL

The	NULL
major	NULL
inducible	NULL
shift	NULL
(	NULL
B	NULL
complex	NULL
)	NULL
appears	NULL
identical	NULL
to	NULL
the	NULL
previously	NULL
reported	NULL
(	NULL
2	NULL
,	NULL
3	NULL
,	NULL
19	NULL
)	NULL
inducible	NULL
shift	NULL
obtained	NULL
with	NULL
similar	NULL
HIV	NULL
«	NULL
xB	NULL
oligonucleotide	NULL
probes	NULL
because	NULL
(	NULL
i	NULL
)	NULL
the	NULL
shift	NULL
was	NULL
not	NULL
detected	NULL
with	NULL
a	NULL
mutant	NULL
enhancer	NULL
,	NULL
nor	NULL
was	NULL
the	NULL
B	NULL
shift	NULL
competed	NULL
for	NULL
by	NULL
this	NULL
mutant	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
;	NULL
the	NULL
mutation	NULL
«	NULL
B/M	NULL
[	NULL
19	NULL
]	NULL
is	NULL
5-CTCACTTTCCGCTGCTCACTTTCCAG-3	NULL
'	NULL
)	NULL
,	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
this	NULL
induced	NULL
shift	NULL
comigrated	NULL
with	NULL
a	NULL
shift	NULL
formed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
Namalwa	NULL
cells	NULL
,	NULL
which	NULL
contain	NULL
a	NULL
constitutively	NULL
activated	NULL
«	NULL
kB	NULL
complex	NULL
(	NULL
13	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
activable	NULL
binding	NULL
activity	NULL
giving	NULL
rise	NULL
to	NULL
this	NULL
shift	NULL
was	NULL
ascribed	NULL
to	NULL
the	NULL
nuclear	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
possibly	NULL
other	NULL
closely	NULL
related	NULL
factors	NULL
(	NULL
2	NULL
,	NULL
3	NULL
,	NULL
8	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Addition	NULL
of	NULL
CsA	NULL
during	NULL
stimulation	NULL
with	NULL
both	NULL
PHA	NULL
and	NULL
PMA	NULL
significantly	NULL
reduced	NULL
the	NULL
major	NULL
shift	NULL
(	NULL
B	NULL
shift	NULL
)	NULL
and	NULL
completely	NULL
abrogated	NULL
the	NULL
A	NULL
shift	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
major	NULL
«	NULL
B	NULL
shift	NULL
was	NULL
only	NULL
partially	NULL
4038	NULL
NOTES	NULL
frgmt	NULL
:	NULL
.	NULL

Kg-HIV	NULL
NE	NULL
:	NULL
£	NULL
+	NULL
+	NULL
t	NULL
+	NULL
+	NULL
+-	NULL
cell	NULL
treatment	NULL
:	NULL
~f	NULL
I	NULL
%	NULL
x	NULL
-	NULL
--	NULL
PHA	NULL
4.5	NULL
hrs	NULL
+	NULL
+	NULL
+	NULL
+	NULL
PMA	NULL
4.5	NULL
hrs	NULL
+	NULL
+	NULL
+	NULL
-	NULL
CsA	NULL
4.5	NULL
hrs	NULL
«	NULL
is	NULL
ats	NULL
d	NULL
«	NULL
b	NULL
@	NULL
»	NULL
@	NULL
@	NULL
&	NULL
©	NULL
ly	NULL
'	NULL
I	NULL
W	NULL
bst	NULL
tut	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Dependence	NULL
of	NULL
CsA	NULL
inhibition	NULL
of	NULL
HIV-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
on	NULL
the	NULL
inducing	NULL
signal	NULL
.	NULL

Complementary	NULL
single-stranded	NULL
oligonucleotide	NULL
fragments	NULL
representing	NULL
the	NULL
HIV	NULL
enhancer	NULL
(	NULL
frgmt	NULL
:	NULL
kB-HIV	NULL
;	NULL
nucleotides	NULL
-104	NULL
to	NULL
-79	NULL
,	NULL
with	NULL
directly	NULL
abutting	NULL
3'-end	NULL
Sstl	NULL
overhangs	NULL
)	NULL
were	NULL
radioactively	NULL
labeled	NULL
with	NULL
polynucleotide	NULL
kinase	NULL
,	NULL
an-nealed	NULL
,	NULL
and	NULL
then	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
.	NULL

Nuclear	NULL
extracts	NULL
(	NULL
NE	NULL
)	NULL
were	NULL
prepared	NULL
from	NULL
untreated	NULL
(	NULL
-	NULL
)	NULL
Jurkat	NULL
cells	NULL
or	NULL
cells	NULL
treated	NULL
for	NULL
4.5	NULL
h	NULL
with	NULL
various	NULL
agents	NULL
(	NULL
PHA	NULL
,	NULL
1	NULL
pg/ml	NULL
;	NULL
PMA	NULL
,	NULL
20	NULL
ng/ml	NULL
;	NULL
CsA	NULL
,	NULL
1	NULL
ug/ml	NULL
)	NULL
(	NULL
+	NULL
)	NULL
by	NULL
hypotonic	NULL
swelling	NULL
of	NULL
cells	NULL
,	NULL
Dounce	NULL
homogeniza-tion	NULL
,	NULL
salt	NULL
extraction	NULL
of	NULL
the	NULL
resulting	NULL
nuclei	NULL
,	NULL
and	NULL
precipitation	NULL
of	NULL
the	NULL
extracted	NULL
nuclear	NULL
proteins	NULL
with	NULL
ammonium	NULL
sulfate	NULL
,	NULL
as	NULL
described	NULL
by	NULL
Shapiro	NULL
et	NULL
al	NULL
.	NULL

(	NULL
23	NULL
)	NULL
.	NULL

Lane	NULL
-	NULL
,	NULL
Free	NULL
labeled	NULL
oligonucleotides	NULL
without	NULL
nuclear	NULL
extracts	NULL
added	NULL
;	NULL
lanes	NULL
+	NULL
,	NULL
nuclear	NULL
extracts	NULL
added	NULL
.	NULL

B	NULL
and	NULL
A	NULL
,	NULL
Positions	NULL
of	NULL
shifts	NULL
B	NULL
and	NULL
A	NULL
,	NULL
respectively	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
two	NULL
constitutively	NULL
present	NULL
complexes	NULL
are	NULL
seen	NULL
.	NULL

suppressed	NULL
when	NULL
the	NULL
broadly	NULL
acting	NULL
,	NULL
mitogenic	NULL
stimuli	NULL
PHA	NULL
and	NULL
PMA	NULL
were	NULL
used	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
activity	NULL
of	NULL
CsA	NULL
with	NULL
each	NULL
agent	NULL
alone	NULL
.	NULL

PHA	NULL
mimics	NULL
induction	NULL
via	NULL
the	NULL
T-cell	NULL
receptor	NULL
,	NULL
while	NULL
PMA	NULL
stimulation	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
mediated	NULL
at	NULL
least	NULL
in	NULL
part	NULL
via	NULL
direct	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C.	NULL
While	NULL
PHA-mediated	NULL
induction	NULL
of	NULL
complexes	NULL
binding	NULL
to	NULL
the	NULL
«	NULL
kB	NULL
enhancer	NULL
was	NULL
completely	NULL
abrogated	NULL
by	NULL
CsA	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lane	NULL
6	NULL
;	NULL
no	NULL
B	NULL
or	NULL
A	NULL
shifts	NULL
)	NULL
,	NULL
the	NULL
PMA-induced	NULL
shift	NULL
was	NULL
not	NULL
at	NULL
all	NULL
affected	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

These	NULL
data	NULL
were	NULL
confirmed	NULL
with	NULL
multiple	NULL
different	NULL
independent	NULL
extracts	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
very	NULL
similar	NULL
or	NULL
identical	NULL
kB	NULL
complexes	NULL
were	NULL
activated	NULL
via	NULL
different	NULL
pathways	NULL
during	NULL
stimulation	NULL
with	NULL
PHA	NULL
versus	NULL
PMA	NULL
and	NULL
that	NULL
these	NULL
pathways	NULL
were	NULL
distinguishable	NULL
by	NULL
their	NULL
sensitivities	NULL
to	NULL
CsA	NULL
.	NULL

As	NULL
shown	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
,	NULL
an	NULL
oligonucleotide	NULL
encompassing	NULL
the	NULL
IL-2	NULL
enhancer	NULL
site	NULL
IIA	NULL
(	NULL
NFAT-l-binding	NULL
site	NULL
)	NULL
bound	NULL
a	NULL
complex	NULL
inducible	NULL
upon	NULL
activation	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
with	NULL
PHA	NULL
and	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
left	NULL
panel	NULL
,	NULL
arrow	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
CsA	NULL
during	NULL
the	NULL
cellular	NULL
activation	NULL
phase	NULL
completely	NULL
abolished	NULL
this	NULL
binding	NULL
.	NULL

When	NULL
a	NULL
mutant	NULL
of	NULL
this	NULL
element	NULL
was	NULL
used	NULL
,	NULL
no	NULL
inducible	NULL
binding	NULL
activity	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
any	NULL
of	NULL
the	NULL
variously	NULL
treated	NULL
cellular	NULL
extracts	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

This	NULL
shows	NULL
the	NULL
sequence	NULL
specificity	NULL
of	NULL
the	NULL
induced	NULL
factor	NULL
,	NULL
as	NULL
do	NULL
previous	NULL
data	NULL
(	NULL
6	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
findings	NULL
reported	NULL
here	NULL
,	NULL
we	NULL
have	NULL
observed	NULL
good	NULL
activation	NULL
of	NULL
NFAT-1	NULL
with	NULL
PHA	NULL
alone	NULL
but	NULL
not	NULL
with	NULL
PMA	NULL
alone	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
J.	NULL
Viror	NULL
.	NULL

-IL	NULL
,	NULL
Hamut	NULL
.	NULL

--	NULL
-	NULL
Co	NULL
P	NULL
frgmt	NULL
--	NULL
IL	NULL
,	NULL
Na	NULL
--	NULL
-	NULL
NE	NULL
:	NULL
Co	NULL
P*	NULL
+	NULL
u	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Sensitivity	NULL
of	NULL
inducible	NULL
NFAT-1	NULL
nuclear	NULL
factor	NULL
complex	NULL
formed	NULL
with	NULL
IL-2	NULL
promoter	NULL
region	NULL
IIA	NULL
to	NULL
CsA	NULL
.	NULL

Double-stranded	NULL
oligonucleotide	NULL
fragments	NULL
(	NULL
frgmt	NULL
)	NULL
representing	NULL
the	NULL
NFAT-1-binding	NULL
site	NULL
IL-2-la	NULL
(	NULL
4	NULL
,	NULL
24	NULL
)	NULL
(	NULL
IL-2	NULL
nucleotides	NULL
-288	NULL
to	NULL
-266	NULL
;	NULL
5'-AAGGAG	NULL
GAAAAACTGTTTCATAC-3	NULL
'	NULL
[	NULL
left	NULL
]	NULL
)	NULL
or	NULL
a	NULL
mutant	NULL
of	NULL
this	NULL
binding	NULL
site	NULL
(	NULL
IL-2-Iamut	NULL
;	NULL
AAGGAGGCAAAACTGTTGCATAC	NULL
[	NULL
right	NULL
]	NULL
)	NULL
(	NULL
both	NULL
sets	NULL
of	NULL
oligonucleotides	NULL
have	NULL
directly	NULL
abutting	NULL
5	NULL
'	NULL
Bg/ll	NULL
[	NULL
upper	NULL
strand	NULL
]	NULL
or	NULL
BamHI	NULL
{	NULL
lower	NULL
strand	NULL
]	NULL
overhangs	NULL
)	NULL
were	NULL
radioactively	NULL
labeled	NULL
by	NULL
filling	NULL
in	NULL
the	NULL
ends	NULL
with	NULL
Klenow	NULL
enzyme	NULL
.	NULL

The	NULL
oligonucleotides	NULL
were	NULL
then	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
,	NULL
and	NULL
the	NULL
resulting	NULL
complexes	NULL
were	NULL
separated	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Nuclear	NULL
extracts	NULL
(	NULL
NE	NULL
)	NULL
were	NULL
prepared	NULL
from	NULL
Jurkat	NULL
cells	NULL
treated	NULL
with	NULL
various	NULL
agents	NULL
,	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Lanes	NULL
Co	NULL
,	NULL
Untreated	NULL
cells	NULL
;	NULL
lanes	NULL
P	NULL
``	NULL
,	NULL
PHA-plus-PMA	NULL
treatment	NULL
;	NULL
lanes	NULL
P°CsA	NULL
,	NULL
PHA	NULL
plus	NULL
PMA	NULL
plus	NULL
CsA	NULL
;	NULL
lanes	NULL
-	NULL
,	NULL
free	NULL
labeled	NULL
oligonucleotides	NULL
without	NULL
nuclear	NULL
extracts	NULL
added	NULL
.	NULL

-	NULL
>	NULL
,	NULL
Position	NULL
of	NULL
the	NULL
inducible	NULL
shift	NULL
.	NULL

The	NULL
additional	NULL
nonspecific	NULL
shift	NULL
was	NULL
largely	NULL
unaffected	NULL
by	NULL
the	NULL
various	NULL
types	NULL
of	NULL
cell	NULL
treatment	NULL
,	NULL
and	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
shift	NULL
is	NULL
unknown	NULL
.	NULL

complete	NULL
suppression	NULL
of	NULL
NFAT-1	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
both	NULL
PHA	NULL
and	NULL
PMA	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
notion	NULL
that	NULL
CsA	NULL
interferes	NULL
with	NULL
some	NULL
necessary	NULL
action	NULL
(	NULL
s	NULL
)	NULL
initiated	NULL
by	NULL
PHA	NULL
but	NULL
not	NULL
with	NULL
those	NULL
initiated	NULL
by	NULL
PMA	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Direct	NULL
addition	NULL
of	NULL
CsA	NULL
to	NULL
a	NULL
prepared	NULL
nuclear	NULL
extract	NULL
from	NULL
activated	NULL
cells	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
factor	NULL
binding	NULL
,	NULL
including	NULL
binding	NULL
of	NULL
kB-binding	NULL
factors	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
which	NULL
suggests	NULL
that	NULL
inhibition	NULL
occurs	NULL
during	NULL
the	NULL
activation	NULL
phase	NULL
of	NULL
NFAT-1	NULL
or	NULL
the	NULL
kB	NULL
complex	NULL
.	NULL

The	NULL
AP-1	NULL
site	NULL
is	NULL
known	NULL
to	NULL
confer	NULL
inducibility	NULL
on	NULL
many	NULL
genes	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
the	NULL
inducible	NULL
binding	NULL
to	NULL
this	NULL
element	NULL
(	NULL
18	NULL
)	NULL
is	NULL
sensitive	NULL
to	NULL
CsA	NULL
as	NULL
well	NULL
,	NULL
we	NULL
performed	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
with	NULL
the	NULL
identical	NULL
CsA-treated	NULL
and	NULL
untreated	NULL
nuclear	NULL
extracts	NULL
described	NULL
above	NULL
.	NULL

Inducible	NULL
binding	NULL
activity	NULL
was	NULL
completely	NULL
insensitive	NULL
to	NULL
CsA	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
,	NULL
even	NULL
when	NULL
PHA	NULL
was	NULL
used	NULL
alone	NULL
as	NULL
a	NULL
stimulus	NULL
.	NULL

This	NULL
experiment	NULL
shows	NULL
that	NULL
some	NULL
activable	NULL
binding	NULL
complexes	NULL
are	NULL
not	NULL
inhibited	NULL
by	NULL
CsA	NULL
,	NULL
and	NULL
therefore	NULL
AP-1	NULL
represents	NULL
a	NULL
control	NULL
for	NULL
the	NULL
inhibition	NULL
of	NULL
the	NULL
NFAT-1	NULL
and	NULL
«	NULL
B	NULL
factors	NULL
.	NULL

This	NULL
experiment	NULL
Vor	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
frgmt	NULL
:	NULL
_	NULL
AP-	NULL
binding	NULL
site	NULL
NE	NULL
-not	NULL
+	NULL
+	NULL
+	NULL
_	NULL
Cell	NULL
treatment	NULL
-	NULL
oof	NULL
+	NULL
+	NULL
+	NULL
PHA	NULL
-	NULL
4.5	NULL
hrs	NULL
.	NULL

+	NULL
+	NULL
=	NULL
PMA	NULL
-	NULL
4.5	NULL
hrs	NULL
=	NULL
+	NULL
=	NULL
t	NULL
CsA	NULL
4.5	NULL
hrs	NULL
.	NULL

FIG	NULL
.	NULL

3	NULL
.	NULL

Inducible	NULL
binding	NULL
to	NULL
an	NULL
AP-1	NULL
site	NULL
is	NULL
insensitive	NULL
to	NULL
CsA	NULL
.	NULL

The	NULL
double-stranded	NULL
oligonucleotide	NULL
fragment	NULL
(	NULL
frgmt	NULL
)	NULL
bearing	NULL
an	NULL
AP-1	NULL
consensus	NULL
core	NULL
sequence	NULL
(	NULL
5-AGAAATAGATGAGTCAAC	NULL
AG-3	NULL
'	NULL
,	NULL
with	NULL
CG	NULL
dinucleotide	NULL
5	NULL
'	NULL
overhangs	NULL
on	NULL
both	NULL
strands	NULL
[	NULL
21	NULL
]	NULL
)	NULL
was	NULL
radioactively	NULL
labeled	NULL
by	NULL
filling	NULL
in	NULL
the	NULL
ends	NULL
with	NULL
Klenow	NULL
enzyme	NULL
and	NULL
was	NULL
subjected	NULL
to	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
with	NULL
nuclear	NULL
extracts	NULL
(	NULL
NE	NULL
)	NULL
from	NULL
cells	NULL
treated	NULL
(	NULL
+	NULL
)	NULL
or	NULL
not	NULL
treated	NULL
(	NULL
-	NULL
)	NULL
as	NULL
indicated	NULL
and	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

The	NULL
inducible	NULL
band	NULL
(	NULL
upper	NULL
band	NULL
)	NULL
is	NULL
essentially	NULL
insensitive	NULL
to	NULL
CsA	NULL
.	NULL

The	NULL
nature	NULL
of	NULL
the	NULL
lower	NULL
constitutively	NULL
present	NULL
band	NULL
shift	NULL
is	NULL
unknown	NULL
.	NULL

Lane	NULL
-	NULL
,	NULL
Free	NULL
labeled	NULL
oligonucleotides	NULL
without	NULL
nuclear	NULL
extracts	NULL
added	NULL
;	NULL
lanes	NULL
+	NULL
,	NULL
nuclear	NULL
extracts	NULL
added	NULL
.	NULL

also	NULL
suggests	NULL
that	NULL
only	NULL
some	NULL
activation	NULL
paths	NULL
initiated	NULL
by	NULL
PHA	NULL
are	NULL
sensitive	NULL
to	NULL
CsA	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
10	NULL
)	NULL
.	NULL

To	NULL
correlate	NULL
the	NULL
signal-dependent	NULL
changes	NULL
in	NULL
factor	NULL
binding	NULL
in	NULL
vitro	NULL
with	NULL
transcriptional	NULL
regulatory	NULL
function	NULL
in	NULL
vivo	NULL
,	NULL
HIV	NULL
wild-type	NULL
or	NULL
mutant	NULL
enhancer-driven	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
constructs	NULL
containing	NULL
a	NULL
minimal	NULL
whey	NULL
acidic	NULL
protein	NULL
(	NULL
WAP	NULL
)	NULL
promoter	NULL
were	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
and	NULL
tested	NULL
for	NULL
CAT	NULL
activity	NULL
after	NULL
various	NULL
cellular	NULL
stimulations	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Several	NULL
independent	NULL
transient	NULL
transfec-tions	NULL
of	NULL
the	NULL
constructs	NULL
were	NULL
carried	NULL
out	NULL
by	NULL
using	NULL
a	NULL
modified	NULL
DEAE	NULL
method	NULL
in	NULL
which	NULL
cells	NULL
are	NULL
slightly	NULL
swollen	NULL
with	NULL
hypotonic	NULL
medium	NULL
before	NULL
transfection	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Following	NULL
a	NULL
36-to	NULL
48-h	NULL
incubation	NULL
period	NULL
after	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
split	NULL
for	NULL
the	NULL
individual	NULL
treatments	NULL
,	NULL
eliminating	NULL
the	NULL
need	NULL
for	NULL
internal	NULL
transfection	NULL
efficiency	NULL
controls	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
then	NULL
treated	NULL
for	NULL
4.5	NULL
h	NULL
with	NULL
PHA	NULL
,	NULL
PMA	NULL
,	NULL
and	NULL
CsA	NULL
,	NULL
and	NULL
CAT	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Regulation	NULL
of	NULL
transcription	NULL
conferred	NULL
by	NULL
the	NULL
HIV	NULL
enhancer	NULL
correlated	NULL
directly	NULL
with	NULL
the	NULL
mobility	NULL
shift	NULL
binding	NULL
studies	NULL
of	NULL
the	NULL
kB	NULL
complex	NULL
.	NULL

Specifically	NULL
,	NULL
CsA	NULL
inhibited	NULL
the	NULL
PHA-derived	NULL
activation	NULL
signal	NULL
but	NULL
not	NULL
the	NULL
PMA	NULL
signal	NULL
.	NULL

Thus	NULL
,	NULL
CsA	NULL
caused	NULL
no	NULL
general	NULL
inhibition	NULL
of	NULL
cellular	NULL
function	NULL
.	NULL

The	NULL
activation	NULL
mediated	NULL
by	NULL
PHA	NULL
and	NULL
PMA	NULL
exceeded	NULL
that	NULL
of	NULL
either	NULL
agent	NULL
alone	NULL
,	NULL
and	NULL
as	NULL
expected	NULL
,	NULL
costimulation	NULL
with	NULL
PHA	NULL
and	NULL
PMA	NULL
was	NULL
only	NULL
partially	NULL
inhibited	NULL
by	NULL
CsA	NULL
.	NULL

The	NULL
transfection	NULL
experiments	NULL
were	NULL
also	NULL
done	NULL
with	NULL
a	NULL
10-fold-lower	NULL
level	NULL
of	NULL
CsA	NULL
(	NULL
0.1	NULL
ug/ml	NULL
)	NULL
,	NULL
and	NULL
we	NULL
observed	NULL
qualitatively	NULL
identical	NULL
results	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
additional	NULL
controls	NULL
,	NULL
the	NULL
HIV	NULL
enhancer	NULL
mutation	NULL
kB/M	NULL
,	NULL
which	NULL
prevented	NULL
binding	NULL
of	NULL
«	NULL
B-like	NULL
complexes	NULL
(	NULL
19	NULL
)	NULL
,	NULL
NOTES	NULL
4039	NULL
CAT	NULL
activity	NULL
(	NULL
x	NULL
control	NULL
)	NULL
control	NULL
PHA/PMA	NULL
PHA/PMA/CsA	NULL
PHA	NULL
PHA/CsA	NULL
PMA	NULL
PMA/CsA	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

Effects	NULL
of	NULL
CsA	NULL
upon	NULL
CAT	NULL
inducibility	NULL
conferred	NULL
by	NULL
HIV	NULL
enhancer	NULL
(	NULL
«	NULL
B-binding	NULL
sites	NULL
)	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

CAT	NULL
activities	NULL
determined	NULL
after	NULL
the	NULL
transfection	NULL
with	NULL
a	NULL
construct	NULL
in	NULL
which	NULL
the	NULL
HIV	NULL
«	NULL
B	NULL
enhancer	NULL
is	NULL
driving	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
are	NULL
shown	NULL
(	NULL
kB-WAP-CAT	NULL
)	NULL
.	NULL

To	NULL
make	NULL
this	NULL
construct	NULL
,	NULL
a	NULL
112-base-pair	NULL
fragment	NULL
from	NULL
the	NULL
mouse	NULL
WAP	NULL
promoter	NULL
,	NULL
extending	NULL
from	NULL
-88	NULL
to	NULL
+24	NULL
(	NULL
Xbal	NULL
to	NULL
KpnI	NULL
)	NULL
(	NULL
5	NULL
)	NULL
,	NULL
was	NULL
cloned	NULL
into	NULL
a	NULL
CAT	NULL
vector	NULL
containing	NULL
no	NULL
promoter	NULL
or	NULL
enhancer	NULL
sequences	NULL
(	NULL
pA1l0	NULL
CAT	NULL
3M	NULL
)	NULL
,	NULL
resulting	NULL
in	NULL
the	NULL
minimal	NULL
promoter	NULL
construct	NULL
WAP-CAT	NULL
.	NULL

Two	NULL
copies	NULL
of	NULL
the	NULL
wild-type	NULL
B-binding	NULL
region	NULL
(	NULL
nucleotides	NULL
-104	NULL
to	NULL
-79	NULL
)	NULL
were	NULL
integrated	NULL
in	NULL
the	NULL
same	NULL
orientation	NULL
into	NULL
an	NULL
Sstl	NULL
site	NULL
at	NULL
-88	NULL
of	NULL
the	NULL
WAP-CAT	NULL
construct	NULL
via	NULL
Ssil	NULL
3	NULL
'	NULL
overhangs	NULL
,	NULL
creating	NULL
«	NULL
B-WAP-CAT	NULL
.	NULL

We	NULL
also	NULL
integrated	NULL
two	NULL
copies	NULL
of	NULL
the	NULL
mutant	NULL
«	NULL
B/M	NULL
(	NULL
see	NULL
above	NULL
)	NULL
to	NULL
create	NULL
kB/M-WAP-CAT	NULL
.	NULL

The	NULL
activities	NULL
under	NULL
various	NULL
types	NULL
of	NULL
cell	NULL
treatment	NULL
(	NULL
indicated	NULL
below	NULL
each	NULL
bar	NULL
)	NULL
are	NULL
expressed	NULL
relative	NULL
to	NULL
the	NULL
total	NULL
CAT	NULL
activity	NULL
found	NULL
with	NULL
untreated	NULL
,	NULL
transfected	NULL
cells	NULL
,	NULL
which	NULL
was	NULL
arbitrarily	NULL
given	NULL
a	NULL
value	NULL
of	NULL
1.0	NULL
.	NULL

Results	NULL
of	NULL
a	NULL
single	NULL
representative	NULL
experiment	NULL
are	NULL
shown	NULL
.	NULL

In	NULL
repeated	NULL
experiments	NULL
with	NULL
the	NULL
same	NULL
construct	NULL
,	NULL
qualitatively	NULL
identical	NULL
results	NULL
were	NULL
obtained	NULL
.	NULL

also	NULL
completely	NULL
abrogated	NULL
the	NULL
inducibility	NULL
of	NULL
CAT	NULL
activity	NULL
by	NULL
PHA	NULL
or	NULL
PMA	NULL
(	NULL
or	NULL
both	NULL
)	NULL
,	NULL
as	NULL
did	NULL
a	NULL
construct	NULL
with	NULL
the	NULL
minimal	NULL
WAP	NULL
promoter	NULL
only	NULL
(	NULL
WAP-CAT	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Our	NULL
transfection	NULL
data	NULL
are	NULL
consistent	NULL
also	NULL
with	NULL
earlier	NULL
transfection	NULL
reports	NULL
which	NULL
demonstrated	NULL
that	NULL
parts	NULL
or	NULL
all	NULL
of	NULL
the	NULL
HIV	NULL
long	NULL
terminal	NULL
repeat	NULL
confers	NULL
inducibility	NULL
by	NULL
signals	NULL
originating	NULL
from	NULL
the	NULL
antigen	NULL
receptor	NULL
or	NULL
originating	NULL
with	NULL
PMA-mediated	NULL
activation	NULL
but	NULL
that	NULL
only	NULL
the	NULL
signal	NULL
from	NULL
the	NULL
antigen	NULL
receptor	NULL
is	NULL
sensitive	NULL
to	NULL
CsA	NULL
(	NULL
26	NULL
,	NULL
28	NULL
)	NULL
.	NULL

CsA	NULL
suppressed	NULL
the	NULL
induction-dependent	NULL
binding	NULL
activity	NULL
in	NULL
T	NULL
cells	NULL
of	NULL
two	NULL
apparently	NULL
unrelated	NULL
DNA-binding	NULL
complexes	NULL
,	NULL
the	NULL
NF-	NULL
«	NULL
B-like	NULL
complex	NULL
formed	NULL
with	NULL
the	NULL
HIV	NULL
enhancer	NULL
and	NULL
the	NULL
NFAT-1	NULL
complex	NULL
formed	NULL
with	NULL
the	NULL
IL-2-IIA	NULL
site	NULL
.	NULL

Additional	NULL
inducible	NULL
DNA-binding	NULL
activities	NULL
may	NULL
be	NULL
affected	NULL
,	NULL
which	NULL
would	NULL
be	NULL
consistent	NULL
with	NULL
a	NULL
broad	NULL
action	NULL
of	NULL
this	NULL
drug	NULL
as	NULL
documented	NULL
by	NULL
the	NULL
relatively	NULL
large	NULL
number	NULL
of	NULL
genes	NULL
in	NULL
T	NULL
cells	NULL
which	NULL
are	NULL
suppressible	NULL
(	NULL
10	NULL
,	NULL
29	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
not	NULL
all	NULL
inducible	NULL
complexes	NULL
were	NULL
suppressed	NULL
,	NULL
as	NULL
exemplified	NULL
by	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
AP-1	NULL
complex	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
drug	NULL
.	NULL

Surprisingly	NULL
,	NULL
suppression	NULL
of	NULL
the	NULL
kB	NULL
complex	NULL
of	NULL
the	NULL
HIV	NULL
enhancer	NULL
in	NULL
T	NULL
cells	NULL
occurred	NULL
only	NULL
when	NULL
the	NULL
cells	NULL
were	NULL
activated	NULL
by	NULL
PHA	NULL
(	NULL
which	NULL
is	NULL
likely	NULL
to	NULL
act	NULL
through	NULL
the	NULL
antigen	NULL
receptor	NULL
)	NULL
but	NULL
not	NULL
when	NULL
activated	NULL
by	NULL
PMA	NULL
.	NULL

Apparently	NULL
,	NULL
identical	NULL
kB	NULL
complexes	NULL
were	NULL
formed	NULL
after	NULL
the	NULL
delivery	NULL
of	NULL
either	NULL
signal	NULL
,	NULL
but	NULL
the	NULL
paths	NULL
for	NULL
trans-ducing	NULL
the	NULL
signal	NULL
must	NULL
have	NULL
been	NULL
different	NULL
.	NULL

When	NULL
PHA	NULL
plus	NULL
PMA	NULL
was	NULL
used	NULL
to	NULL
activate	NULL
cells	NULL
,	NULL
inhibition	NULL
of	NULL
the	NULL
kB	NULL
complex	NULL
was	NULL
only	NULL
partial	NULL
,	NULL
which	NULL
suggests	NULL
that	NULL
the	NULL
PMA-initiated	NULL
4040	NULL
NOTES	NULL
signals	NULL
remained	NULL
unaffected	NULL
by	NULL
CsA	NULL
.	NULL

Since	NULL
the	NULL
NFAT-1	NULL
factor	NULL
required	NULL
stimulation	NULL
by	NULL
PHA	NULL
as	NULL
opposed	NULL
to	NULL
PMA	NULL
,	NULL
it	NULL
was	NULL
very	NULL
sensitive	NULL
to	NULL
CsA	NULL
even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
both	NULL
PHA	NULL
and	NULL
PMA	NULL
.	NULL

After	NULL
completion	NULL
of	NULL
this	NULL
work	NULL
,	NULL
a	NULL
related	NULL
report	NULL
appeared	NULL
which	NULL
demonstrated	NULL
CsA	NULL
inhibition	NULL
of	NULL
the	NULL
NFAT-1-	NULL
and	NULL
the	NULL
«	NULL
B-binding	NULL
activities	NULL
in	NULL
PHA-PMA-stimulated	NULL
T	NULL
cells	NULL
(	NULL
7	NULL
)	NULL
.	NULL

The	NULL
partial	NULL
inhibition	NULL
of	NULL
the	NULL
<	NULL
B-binding	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
after	NULL
induction	NULL
with	NULL
these	NULL
combined	NULL
signals	NULL
was	NULL
not	NULL
analyzed	NULL
further	NULL
,	NULL
however	NULL
.	NULL

The	NULL
results	NULL
of	NULL
the	NULL
transfection	NULL
experiments	NULL
with	NULL
HIV	NULL
enhancer-driven	NULL
CAT	NULL
constructs	NULL
demonstrated	NULL
that	NULL
the	NULL
in	NULL
vivo	NULL
effects	NULL
closely	NULL
corresponded	NULL
to	NULL
the	NULL
results	NULL
of	NULL
«	NULL
B-binding	NULL
studies	NULL
in	NULL
vitro	NULL
.	NULL

The	NULL
PHA-stimulated	NULL
but	NULL
not	NULL
the	NULL
PMA-stimulated	NULL
cells	NULL
were	NULL
sensitive	NULL
to	NULL
CsA	NULL
.	NULL

Thus	NULL
,	NULL
CsA	NULL
appears	NULL
to	NULL
inhibit	NULL
a	NULL
step	NULL
(	NULL
s	NULL
)	NULL
in	NULL
cellular	NULL
activation	NULL
which	NULL
follows	NULL
PHA	NULL
or	NULL
antigen	NULL
receptor	NULL
stimulation	NULL
but	NULL
does	NULL
not	NULL
inhibit	NULL
the	NULL
PMA	NULL
signal	NULL
.	NULL

Since	NULL
it	NULL
is	NULL
known	NULL
that	NULL
stimulation	NULL
via	NULL
the	NULL
antigen	NULL
receptor	NULL
leads	NULL
to	NULL
production	NULL
of	NULL
inositol	NULL
phosphate	NULL
derivatives	NULL
and	NULL
diacylglycerol	NULL
even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CsA	NULL
(	NULL
12	NULL
)	NULL
,	NULL
the	NULL
suppression	NULL
must	NULL
occur	NULL
downstream	NULL
of	NULL
these	NULL
second	NULL
messengers	NULL
or	NULL
involve	NULL
an	NULL
as	NULL
yet	NULL
unidentified	NULL
second	NULL
messenger	NULL
.	NULL

Also	NULL
,	NULL
activation	NULL
of	NULL
AP-1	NULL
with	NULL
PHA	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
CsA	NULL
,	NULL
which	NULL
suggests	NULL
that	NULL
only	NULL
some	NULL
PHA-derived	NULL
signals	NULL
are	NULL
suppressible	NULL
.	NULL

It	NULL
is	NULL
not	NULL
known	NULL
what	NULL
links	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
kB	NULL
and	NULL
NFAT-1	NULL
factors	NULL
.	NULL

NFAT-1	NULL
appears	NULL
to	NULL
involve	NULL
the	NULL
synthesis	NULL
of	NULL
an	NULL
induced	NULL
gene	NULL
,	NULL
since	NULL
cycloheximide	NULL
interferes	NULL
with	NULL
NFAT-1	NULL
activation	NULL
(	NULL
4	NULL
,	NULL
24	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
the	NULL
«	NULL
B	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
is	NULL
already	NULL
present	NULL
in	NULL
the	NULL
cell	NULL
and	NULL
requires	NULL
only	NULL
release	NULL
from	NULL
a	NULL
cytoplasmic	NULL
inhibitor	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Considering	NULL
that	NULL
several	NULL
similar	NULL
but	NULL
possibly	NULL
distinct	NULL
nuclear	NULL
factors	NULL
may	NULL
bind	NULL
to	NULL
the	NULL
HIV	NULL
«	NULL
B	NULL
region	NULL
,	NULL
we	NULL
can	NULL
not	NULL
rule	NULL
out	NULL
that	NULL
such	NULL
factors	NULL
are	NULL
separately	NULL
activated	NULL
depending	NULL
on	NULL
the	NULL
inducing	NULL
signal	NULL
.	NULL

This	NULL
could	NULL
be	NULL
the	NULL
cause	NULL
of	NULL
the	NULL
observed	NULL
differential	NULL
sensitivity	NULL
to	NULL
CsA	NULL
.	NULL

Whether	NULL
the	NULL
same	NULL
or	NULL
a	NULL
distinct	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
binds	NULL
as	NULL
a	NULL
result	NULL
of	NULL
the	NULL
two	NULL
activation	NULL
signals	NULL
,	NULL
these	NULL
signal-trans-ducing	NULL
paths	NULL
converge	NULL
functionally	NULL
at	NULL
the	NULL
DNA	NULL
level	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
the	NULL
transfection	NULL
experiments	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
different	NULL
kinases	NULL
(	NULL
or	NULL
other	NULL
modifications	NULL
)	NULL
effect	NULL
the	NULL
release	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
from	NULL
its	NULL
inhibitor	NULL
(	NULL
1	NULL
)	NULL
and	NULL
that	NULL
some	NULL
of	NULL
these	NULL
kinases	NULL
in	NULL
turn	NULL
are	NULL
regulated	NULL
by	NULL
distinct	NULL
signaling	NULL
pathways	NULL
.	NULL

We	NULL
thank	NULL
A.	NULL
S.	NULL
Fauci	NULL
and	NULL
K.	NULL
Kelly	NULL
for	NULL
support	NULL
and	NULL
encouragement	NULL
and	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
,	NULL
D.	NULL
Levens	NULL
for	NULL
the	NULL
AP-1	NULL
oligonucleotide	NULL
,	NULL
and	NULL
M.	NULL
Brunvand	NULL
for	NULL
IL-2	NULL
oligonucleotides	NULL
and	NULL
initial	NULL
help	NULL
with	NULL
nuclear	NULL
extraction	NULL
.	NULL

A.S.	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
Stiftung	NULL
Volkswagenwerk	NULL
.	NULL

LITERATURE	NULL
CITED	NULL
1	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

I	NULL
kappa	NULL
B	NULL
:	NULL
a	NULL
specific	NULL
inhibitor	NULL
of	NULL
the	NULL
NF-kappa	NULL
B	NULL
transcription	NULL
factor	NULL
.	NULL

Science	NULL
242	NULL
:	NULL
540-545	NULL
.	NULL

2	NULL
.	NULL

Bohnlein	NULL
,	NULL
E.	NULL
,	NULL
J.	NULL
W.	NULL
Lowenthal	NULL
,	NULL
M.	NULL
Siekevitz	NULL
,	NULL
D.	NULL
W.	NULL
Ballard	NULL
,	NULL
B.	NULL
R.	NULL
Franza	NULL
,	NULL
and	NULL
W.	NULL
Greene	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
same	NULL
inducible	NULL
nuclear	NULL
protein	NULL
regulates	NULL
mitogen	NULL
activation	NULL
of	NULL
both	NULL
the	NULL
interleukin-2	NULL
receptor-alpha	NULL
gene	NULL
and	NULL
type	NULL
1	NULL
HIV	NULL
.	NULL

Cell	NULL
53:827-836	NULL
.	NULL

3	NULL
.	NULL

Bohnlein	NULL
,	NULL
E.	NULL
,	NULL
M.	NULL
Sieckevitz	NULL
,	NULL
D.	NULL
W.	NULL
Ballard	NULL
,	NULL
J.	NULL
W.	NULL
Lowenthal	NULL
,	NULL
L.	NULL
Rimsky	NULL
,	NULL
H.	NULL
Bogerd	NULL
,	NULL
J.	NULL
Hoffman	NULL
,	NULL
Y.	NULL
Wano	NULL
,	NULL
B.	NULL
R.	NULL
Franza	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1989	NULL
.	NULL

Stimulation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
enhancer	NULL
by	NULL
the	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I	NULL
tax	NULL
gene	NULL
product	NULL
involves	NULL
the	NULL
action	NULL
of	NULL
inducible	NULL
cellular	NULL
proteins	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

63:1578-1586	NULL
.	NULL

4	NULL
.	NULL

Brunvand	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
A.	NULL
Schmidt	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1989	NULL
.	NULL

Nuclear	NULL
factors	NULL
interacting	NULL
with	NULL
the	NULL
mitogen-responsive	NULL
regulatory	NULL
region	NULL
of	NULL
the	NULL
interleukin-2	NULL
gene	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

263:18904-18910	NULL
.	NULL

5	NULL
.	NULL

Campbell	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
J.	NULL
M.	NULL
Rosen	NULL
,	NULL
L.	NULL
G.	NULL
Hennighausen	NULL
,	NULL
U.	NULL
Strech-Jurk	NULL
,	NULL
and	NULL
A.	NULL
E.	NULL
Sippel	NULL
.	NULL

1984	NULL
.	NULL

Comparison	NULL
of	NULL
the	NULL
whey	NULL
acidic	NULL
protein	NULL
genes	NULL
of	NULL
the	NULL
rat	NULL
and	NULL
mouse	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

12	NULL
:	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

J.	NULL
ViroL	NULL
.	NULL

8685-8697.	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
J.-P.	NULL
Shaw	NULL
,	NULL
M.	NULL
R.	NULL
Bush	NULL
,	NULL
R.	NULL
E.	NULL
Replogle	NULL
,	NULL
R.	NULL
Belagaje	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
antigen	NULL
receptor	NULL
response	NULL
elements	NULL
within	NULL
the	NULL
interleukin-2	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:1715-1724.	NULL
.	NULL

Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
C.	NULL
L.	NULL
Verweij	NULL
,	NULL
D.	NULL
B.	NULL
Durand	NULL
,	NULL
K.	NULL
M.	NULL
Higgins	NULL
,	NULL
E.	NULL
Lacy	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1989	NULL
.	NULL

Cyclosporin	NULL
A	NULL
specifically	NULL
inhibits	NULL
function	NULL
of	NULL
nuclear	NULL
proteins	NULL
involved	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Science	NULL
246:1617-1620.	NULL
.	NULL

Franza	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
M.	NULL
Z.	NULL
Gilman	NULL
,	NULL
W.	NULL
Ryan	NULL
,	NULL
and	NULL
B.	NULL
Clarkson	NULL
.	NULL

1987	NULL
.	NULL

Characterization	NULL
of	NULL
cellular	NULL
proteins	NULL
recognizing	NULL
the	NULL
HIV	NULL
enhancer	NULL
using	NULL
a	NULL
microscale	NULL
DNA-affinity	NULL
precipitation	NULL
assay	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
330:391-395.	NULL
.	NULL

Granelli-Piperno	NULL
,	NULL
A.	NULL
,	NULL
L.	NULL
Andrus	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Steinman	NULL
.	NULL

1986	NULL
.	NULL

Lymphokine	NULL
and	NULL
nonlymphokine	NULL
mRNA	NULL
levels	NULL
in	NULL
stimulated	NULL
human	NULL
T	NULL
cells	NULL
:	NULL
kinetics	NULL
,	NULL
mitogen	NULL
requirements	NULL
,	NULL
and	NULL
effects	NULL
of	NULL
cyclosporin	NULL
A.	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

163:922-937	NULL
.	NULL

Gunter	NULL
,	NULL
K.	NULL
C.	NULL
,	NULL
S.	NULL
G.	NULL
Irving	NULL
,	NULL
P.	NULL
F.	NULL
Zipfel	NULL
,	NULL
U.	NULL
Siebenlist	NULL
,	NULL
and	NULL
K.	NULL
Kelly	NULL
.	NULL

1989	NULL
.	NULL

Cyclosporin	NULL
A-mediated	NULL
inhibition	NULL
of	NULL
mitogen-induced	NULL
gene	NULL
transcription	NULL
is	NULL
specific	NULL
for	NULL
the	NULL
mitogenic	NULL
stimulus	NULL
and	NULL
cell	NULL
type	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

142:3286-3291	NULL
.	NULL

Hoyos	NULL
,	NULL
B.	NULL
,	NULL
D.	NULL
W.	NULL
Ballard	NULL
,	NULL
E.	NULL
Bohnlein	NULL
,	NULL
M.	NULL
Sickevitz	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1989	NULL
.	NULL

Kappa	NULL
B-specific	NULL
DNA	NULL
binding	NULL
proteins	NULL
:	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
human	NULL
interleukine-2	NULL
gene	NULL
expression	NULL
.	NULL

Science	NULL
244:457-460	NULL
.	NULL

Imboden	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
A.	NULL
Weiss	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
initiation	NULL
of	NULL
human	NULL
T	NULL
lymphocyte	NULL
activation	NULL
.	NULL

Prog	NULL
.	NULL

Allerg	NULL
.	NULL

42:246-279	NULL
.	NULL

Kawakami	NULL
,	NULL
K.	NULL
,	NULL
C.	NULL
Scheidereit	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1988	NULL
.	NULL

Identification	NULL
and	NULL
purification	NULL
of	NULL
a	NULL
human	NULL
immunoglobulin-enhancer-binding	NULL
protein	NULL
(	NULL
NF-kB	NULL
)	NULL
that	NULL
activates	NULL
transcription	NULL
from	NULL
a	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
promoter	NULL
in	NULL
vitro	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:4700-4704	NULL
.	NULL

Kronke	NULL
,	NULL
M.	NULL
,	NULL
W.	NULL
J.	NULL
Leonard	NULL
,	NULL
J.	NULL
M.	NULL
Depper	NULL
,	NULL
S.	NULL
K.	NULL
Arya	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
T.	NULL
A.	NULL
Waldmann	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1984	NULL
.	NULL

Cyclosporin	NULL
A	NULL
inhibits	NULL
T-cell	NULL
growth	NULL
factor	NULL
gene	NULL
expression	NULL
at	NULL
the	NULL
level	NULL
of	NULL
mRNA	NULL
transcription	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
81:5214-5218	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
C.	NULL
M.	NULL
Fan	NULL
,	NULL
T.	NULL
Maniatis	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
involvement	NULL
of	NULL
NF-KB	NULL
in	NULL
beta-interferon	NULL
gene	NULL
regulation	NULL
reveals	NULL
its	NULL
role	NULL
as	NULL
widely	NULL
inducible	NULL
mediator	NULL
of	NULL
signal	NULL
transduc-tion	NULL
.	NULL

Cell	NULL
57:287-294	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
A.	NULL
Kuang	NULL
,	NULL
A.	NULL
Gifford	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

NF-KB	NULL
protein	NULL
purification	NULL
from	NULL
bovine	NULL
spleen	NULL
:	NULL
nucleotide	NULL
stimulation	NULL
and	NULL
binding	NULL
site	NULL
specificity	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:8825-8829	NULL
.	NULL

Lieber	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
J.	NULL
E.	NULL
Hesse	NULL
,	NULL
K.	NULL
Mizuuchi	NULL
,	NULL
and	NULL
M.	NULL
Gellert	NULL
.	NULL

1987	NULL
.	NULL

Developmental	NULL
stage	NULL
specificity	NULL
of	NULL
the	NULL
lymphoid	NULL
V	NULL
(	NULL
D	NULL
)	NULL
J	NULL
recombination	NULL
activity	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

1	NULL
;	NULL
751-761	NULL
.	NULL

Muegge	NULL
,	NULL
K.	NULL
,	NULL
T.	NULL
M.	NULL
Williams	NULL
,	NULL
J.	NULL
Kant	NULL
,	NULL
M.	NULL
Karin	NULL
,	NULL
R.	NULL
Chiu	NULL
,	NULL
A.	NULL
Schmidt	NULL
,	NULL
U.	NULL
Siebenlist	NULL
,	NULL
H.	NULL
Young	NULL
,	NULL
and	NULL
S.	NULL
K.	NULL
Durum	NULL
.	NULL

1989	NULL
.	NULL

Interleukin-1	NULL
costimulatory	NULL
activity	NULL
on	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
via	NULL
AP-1	NULL
.	NULL

Science	NULL
246:249-251	NULL
.	NULL

Nabel	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

An	NULL
inducible	NULL
transcription	NULL
factor	NULL
activates	NULL
expression	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
326:711-713	NULL
.	NULL

Neumann	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
C.	NULL
A.	NULL
Morency	NULL
,	NULL
and	NULL
K.	NULL
O.	NULL
Russian	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
novel	NULL
rapid	NULL
assay	NULL
for	NULL
chloramphenicol	NULL
acetyltransferase	NULL
gene	NULL
expression	NULL
.	NULL

BioTechniques	NULL
5:444-447	NULL
.	NULL

Quinn	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
N.	NULL
Holbrook	NULL
,	NULL
and	NULL
D.	NULL
Levens	NULL
.	NULL

1987	NULL
.	NULL

Binding	NULL
of	NULL
a	NULL
cellular	NULL
protein	NULL
to	NULL
the	NULL
gibbon	NULL
ape	NULL
leukemia	NULL
virus	NULL
enhancer	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

7:2735-2744	NULL
.	NULL

Schibuya	NULL
,	NULL
H.	NULL
,	NULL
M.	NULL
Yoneyama	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1989	NULL
.	NULL

Involvement	NULL
of	NULL
a	NULL
common	NULL
transcription	NULL
factor	NULL
in	NULL
the	NULL
regulated	NULL
expression	NULL
of	NULL
IL-2	NULL
and	NULL
IL-2	NULL
receptor	NULL
genes	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

1:43-49	NULL
.	NULL

Shapiro	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
,	NULL
W.	NULL
W.	NULL
Wahli	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Keller	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
high-efficiency	NULL
HeLa	NULL
cell	NULL
nuclear	NULL
transcription	NULL
extract	NULL
.	NULL

DNA	NULL
7:47-55	NULL
.	NULL

Shaw	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
P.	NULL
J.	NULL
Utz	NULL
,	NULL
D.	NULL
B.	NULL
Durand	NULL
,	NULL
J.	NULL
J.	NULL
Toole	NULL
,	NULL
E.	NULL
A.	NULL
Emmel	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1989	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
putative	NULL
regulator	NULL
of	NULL
early	NULL
T	NULL
cell	NULL
activation	NULL
genes	NULL
.	NULL

Science	NULL
241:202-205	NULL
.	NULL

Shevach	NULL
,	NULL
E.	NULL
M.	NULL
1985	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
cyclosporin	NULL
A	NULL
on	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

3:397-423	NULL
.	NULL

Siekevitz	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
M.	NULL
Dukovich	NULL
,	NULL
N.	NULL
Peffer	NULL
,	NULL
F.	NULL
Wong	NULL
Vor	NULL
.	NULL

64	NULL
,	NULL
1990	NULL
27	NULL
.	NULL

Staal	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1987	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
by	NULL
28	NULL
.	NULL

T	NULL
cell	NULL
mitogens	NULL
and	NULL
the	NULL
trans-activator	NULL
protein	NULL
of	NULL
HTLV-I	NULL
.	NULL

Science	NULL
238:1575-1578	NULL
.	NULL

Staudt	NULL
,	NULL
L.	NULL
M.	NULL
,	NULL
H.	NULL
Singh	NULL
,	NULL
R.	NULL
Sen	NULL
,	NULL
T.	NULL
Wirth	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

Sharp	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
lymphoid-specific	NULL
protein	NULL
binding	NULL
to	NULL
the	NULL
29.	NULL
octamer	NULL
motif	NULL
of	NULL
immunoglobulin	NULL
genes	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
323	NULL
:	NULL
640-643	NULL
.	NULL

NOTES	NULL
4041	NULL
Tong-Starksen	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1989	NULL
.	NULL

Signalling	NULL
through	NULL
T	NULL
lymphocyte	NULL
surface	NULL
proteins	NULL
,	NULL
TCR/CD3	NULL
and	NULL
CD28	NULL
,	NULL
activates	NULL
the	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

142:702-707	NULL
.	NULL

Zipfel	NULL
,	NULL
P.	NULL
F.	NULL
,	NULL
S.	NULL
G.	NULL
Irving	NULL
,	NULL
K.	NULL
Kelly	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1989	NULL
.	NULL

Complexity	NULL
of	NULL
the	NULL
primary	NULL
genetic	NULL
response	NULL
to	NULL
mitogenic	NULL
activation	NULL
of	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9:1041-1048	NULL
.	NULL

